Novo Nordisk has advised the TGA there will be continued, limited
intermittent availability in Australia of Ozempic®
(semaglutide), a medicine approved for use in adults with type 2
diabetes, until December 2024.
The reason for the extended intermittent availability is the
continued, unprecedented strong demand for Ozempic®
(semaglutide) in Australia and around the world.
Whilst Ozempic® (semaglutide) supply in Australia
improved significantly in 2023, there continues to be strong
Novo Nordisk is working hard to satisfy demand to the greatest
extent possible. Our deliveries of Ozempic® (semaglutide)
to Australia in 2023 were significantly more than compared to 2022
Novo Nordisk continues to expand its global manufacturing capacity
to meet the strong demand for Ozempic® (semaglutide) for
now and into the future. Our global manufacturing facilities are
running 24 hours a day, seven days a week. By the end of 2023, we will
have invested more than $US5B in the past two years to open new
production lines and facilities.
Novo Nordisk, the TGA, AMA, RACGP, Pharmacy Guild and
organisations representing diabetes and obesity will continue to
work together and will continue to monitor the situation, and
provide updated guidance as required
It’s important to continue to follow the joint guidance
issued by the TGA and various professional bodies on this
matter, and additional information
about Ozempic® (semaglutide) supply on the TGA
website. Novo Nordisk has and will continue to work with the TGA
on providing updates on this matter.